Escape of HIV-1 is associated with lack of V3 domain-specific antibodies in vivo

Clinical and Experimental Immunology

Volumn 107, Issue 1, 1997, Pages 15-20

  Schreiber, M ^a   Muller H ^a   Wachsmuth, C ^a   Laue, T ^a   Hufert, F T ^b   Van Laer, M D ^b   Schmitz, H ^a  

^a BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Antibody; HIV; V3 loop; Variation; Viral escape

Indexed keywords

CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBODY RESPONSE; ARTICLE; CASE REPORT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPH NODE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE SUBPOPULATION;

EID: 0031014364     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-909.x     Document Type: Article

References (39)

1. LaRosa GJ, Davide JP, Weinehold K et al. Conserved sequence and structural elements in the HIV-I principle neutralizing determinant. Science 1990; 249:932-5.
2. Moore JP, McCutchan FE, Poon SW et al. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol 1994; 68:8350-64.
3. Moore JP, Trkola A, Korber B et al. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J Virol 1995; 69:122-30.
4. Spear GT, Tukefman DM, Sharpe S, Ghassemi M, Zolla Pazner S. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization. Virology 1994; 204:609-15.
5. Homsy J, Meyer M, Levy JA. Serum enhancement of human immunodeficiency virus (HIV) correlates with disease in HIV-infected individuals. J Virol 1990; 64:1437-40.
6. Jiang SB, Lin K, Neurath AR. Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41. J Exp Med 1991; 174:1557-63.
7. Kliks SC, Shioda T, Haigwood NL, Levy JA. V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993; 90:11518-22.
8. Carrow EW, Vujcic LK, Glass WL et al. High prevalence of antibodies to the gp 120 V3 region principal neutralizing determinant of HIV-1 MN in sera from Africa and the Americus. AIDS Res Hum Retrovir 1991; 7:831-8.
9. Zwart G, Langedijk H, van der Hoek L et al. Immunodominance and antigenic variation of the principle neutralization domain of HIV-1. Virology 1991; 181:481-9.
10. Berman PW, Groopman JE, Gregory T et al. HIV-1 challenge of chimpanzees immunized with recombinant gp120. Proc Natl Acad Sci USA 1988; 85:5200-4.
11. Goudsmit J, Juiken CL, Nara PL. Linear versus conformational variation of V3 neutralization domains of HIV-1 during experimental and natural infection. AIDS 1989; 3:S119-23.
12. Moore JP, Cao Y, Ho DD, Koup RA. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 1994; 68:5142-55.
13. Girard M, Kieny MP, Renter A et al. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci USA 1991; 88:542-6.
14. Piatak M, Saag MS Jr, Yang LC et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993; 259:1749-54.
15. Schnittman SM, Greenhouse JJ, Lane HC. Pierce PF, Fauci AS. Frequent detection of HIV-1-specific mRNAs in infected individuals suggests ongoing active viral expression in all stages of disease. AIDS Res Hum Retrovir 1991; 7:361-7.
16. Albert J, Abrahamsson B, Nagy K et al Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990; 4:107-12.
17. di Marzo Veronese F, Reitz MS. Gupta G Jr et al. Loss of a neutralizing epitope by a spontaneous point mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker. J Biol Chem 1993; 268:25894-901.
18. McKeating JA, Bennett J, Zolla Pazner S et al. Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120. J Virol 1993; 67:5216-25.
19. Pircher H, Moskophidis D, Rohrer U, Burki K, Hengartner H. Zinkernagel RM. Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature 1990; 346:629-33.
20. von Gegerfelt A, Albert J, Morfeldt-Manson L, Broliden K, Fenyo EM. Isolate-specitic neutralizing antibodies in patients with progressive HIV-1-related disease. Virology 1991; 185:162-8.
21. Schreiber M, Petersen H, Wachsmuth C, Müller H, Hufert F, Schmitz H. Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum. J Virol 1994; 68:3908-16.
22. Schreiber M, Wachsmuth C, Müller H, Hagen C, Schmitz H, van Lunzen J. Loss of antibody reactivity directed against the V3 domain of certain human immunodeficiency virus type 1 variants during disease progression. J Gen Virol 1996; 77:2403-14.
23. + hematopoietic progenitor cells are not a major reservoir of the human immunodeficiency virus. Blood 1990; 76:1281-6.
24. Bosch V, Pawlita M. Mutational analysis of the human immunodeficiency virus type 1 env gene product proteolytic cleavage site. J Virol 1990; 64:2337-44.
25. Nara PL, Smit L, Dunlop N et al. Emergency of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J Virol 1990; 64:3779-91.
26. Reitz MS, Wilson C, Naugle C, Gallo RC, Robert Guroff M. Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell 1988; 54:57-63.
27. Ariyoshi K, Harwood E, Chiengsong Popov R, Weber J. Is clearance of HIV-1 viraemia at seroconversion mediated by neutralising antibodies? Lancet 1992; 340:1257-8.
28. Robert Guroff M, Roilides E, Muldoon R et al. Human immunodeficiency virus (HIV) type 1 strain MN neutralizing antibody in HIV-infected children: correlation with clinical status and prognostic value. J Infect Dis 1993; 167:538-46.
29. Pincus SH, Messer KG, Nara PL, Blattner WA. Colclough G, Reitz M. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers. J Clin Invest 1994; 93:2505-13.
30. Lu W, Shih WK, Tourani JM, Eme D, Alter HJ. Andrieu JM. Lack of isolate-specific neutralizing activity is correlated with an increased viral burden in rapidly progressing HIV-1-infected patients. AIDS 1993; 7:S9l-99.
31. Cavacini LA, Emes CL, Power J et al. Loss of serum antibodies to a conformational epitope of HIV-1/gp120 identified by a human monoclonal antibody is associated with disease progression. J Acquir Immune Defic Syndr 1993; 6:1093-102.
32. Fenouillet E, Blanes N, Benjouad A, Gluckmann JC. Anti-V3 antibody reactivity correlates with clinical stage of HIV-1 infection and with serum neutralizing activity. Clin Exp Immunol 1995; 99:419-24.
33. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-6.
34. Wei X, Ghosh SK, Taylor ME et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117-22.
35. Simmonds P, Zhang LQ, McOmish F, Balfe P, Ludlam CA. Leigh Brown AJ. Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis. J Virol 1991; 65:6266-76.,
36. Holmes EC, Zhang LQ, Robertson P et al. The molecular epidemiology of human immunodeficiency virus type 1 in Edinburgh. J Int Dis 1995; 171:45-53.
37. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane domain, G-protein coupled receptor. Science 1996; 272:872-7.
38. Alkhatib G, Combadiere C, Broder CC et al. CC CKR5: a rantes, MIP1α. MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272:1955-8.
39. Miedema ML, Petit AJC, Terpstra FG et al. Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. J Clin Invest 1988; 82:1908-14.